A year after the US Food and Drug Administration’s first-ever public hearing on cannabidiols, a research collaborative warns that a public health risk is growing as demand soars with clinical data still needed for agency guidance on using the ingredients in non-drug products.
The Collaborative for CBD Science and Safety says since 2016, investment in cannabis research has increased 65%, from $115m to...








